^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NRAS mutation

    i
    Other names: NRAS1, HRAS1, N-Ras Protein Part 4, Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, NRAS, Neuroblastoma RAS Viral Oncogene Homolog, NRAS Proto-Oncogene, GTPase
    Entrez ID:
    4893
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    1d
    The Molecular Heterogeneity of NRAS Variants in Thyroid Nodules. (PubMed, Otolaryngol Head Neck Surg)
    NRAS p.Q61R/K comprises 99% of reported NRAS variants. TERTp is the most frequent co-mutation. Among NRAS p.Q61R/K nodules, there are 2 different clusters of samples based on the activity of hallmarks of cancer pathways. Further studies correlating these clusters with clinical and pathological outcomes are necessary.
    Journal
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • TERT (Telomerase Reverse Transcriptase) • MAPK1 (Mitogen-activated protein kinase 1) • EIF1AX (Eukaryotic Translation Initiation Factor 1A X-Linked)
    |
    BRAF mutation • NRAS mutation • RAS mutation • NRAS Q61
    |
    Afirma® Genomic Sequencing Classifier
    2d
    A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Ruijin Hospital
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1)
    |
    KRAS mutation • NRAS mutation • RAS mutation • HRAS mutation • KRAS G12 • NRAS G12
    6d
    Impact of Driver Genetic Alterations on Survival in Metastatic Colorectal Cancer Patients from a Genetically Homogeneous Sardinian Population: A Real-World Study. (PubMed, Cancers (Basel))
    Increasing age at the time of first-line therapy for advanced disease stage was associated with a statistically significant increase in the hazard of death (p = 0.031). In the advanced disease stage, RAS/BRAF wild-type colorectal cancers were significantly associated with a survival advantage.
    Journal • Real-world evidence
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • BRAF wild-type • RAS mutation
    6d
    Performance of Seven-Gene Panel Testing for Risk Stratification of Thyroid Nodules with Indeterminate Cytology Results. (PubMed, Int J Mol Sci)
    Depending on the Bethesda category, the positive predictive value for malignancy of the seven-gene panel ranged between 18.18% (Bethesda III) and 91.07% (Bethesda V), while the negative predictive value ranged between 93.92% (Bethesda III) and 24.14% (Bethesda V). In conclusion, molecular testing with the seven-gene panel can improve ROM estimation in cytopathologically indeterminate thyroid nodules, but its clinical utility depends on the detected gene alteration.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RET (Ret Proto-Oncogene) • HRAS (Harvey rat sarcoma viral oncogene homolog) • RAS (Rat Sarcoma Virus) • NCOA4 (Nuclear Receptor Coactivator 4) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PAX8 (Paired box 8)
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600 • RET fusion • RAS mutation • RET mutation • HRAS mutation
    6d
    Sarcoidosis-Like Granulomatous Reaction During Adjuvant Pembrolizumab for High-Risk Resected Melanoma. (PubMed, Case Rep Oncol Med)
    This phenomenon may have prognostic implications and warrants multidisciplinary management approach. This case highlights the importance of recognizing immune-mediated SLRs during immunotherapy, particularly in melanoma, and underscores the need for a high index of suspicion and further evidence to guide optimal management strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation • NRAS Q61
    |
    Keytruda (pembrolizumab)
    6d
    KRAS/NRAS/BRAF Mutations and Mismatch Repair Deficiency in Patients with Early-Onset Colorectal Cancer: A Clinicopathological Analysis. (PubMed, Int J Surg Pathol)
    KRAS mutations were more frequent in dMMR tumors than in MMR-proficient tumors (63.8% vs 40.8%).ConclusionGenetic mutations in the RAS/RAF pathway and dMMR status are associated with distinct clinicopathological features in patients with early-onset CRC. dMMR is a potentially favorable prognostic marker.
    Journal • Mismatch repair
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
    |
    BRAF V600E • KRAS mutation • MSI-H/dMMR • BRAF mutation • NRAS mutation • BRAF V600 • KIT mutation • RAS mutation
    8d
    Synchronous metastatic differentiated high-grade thyroid carcinoma in lymph node from classic papillary thyroid carcinoma: a case report and literature review. (PubMed, Front Oncol)
    Genetic testing of the PMs revealed no mutations in BRAF, KRAS, or NRAS, and no RET rearrangement. The patient's condition was subsequently managed with targeted therapy and immunotherapy, which achieved disease stabilization.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • RET rearrangement
    10d
    Comparative efficacy of donor lymphocyte infusions in augmenting graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies. (PubMed, Acta Haematol)
    DLI is an effective treatment strategy for post-transplant relapse of all myeloid malignancies, with specific genetic subtypes showing poorer outcomes and survival.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1)
    |
    TP53 mutation • KRAS mutation • NRAS mutation
    12d
    NF1 mutation may be associated with lung-tropic metastasis in cutaneous melanoma: a genomic analysis of 520 patients. (PubMed, Clin Exp Metastasis)
    NF1 mutation is the strongest gene-level correlate of lung-selective metastasis in cutaneous melanoma. The NF1-mutant subtype may represent a dual-biomarker population and could warrant both pulmonary surveillance and prospective evaluation for immunotherapy.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • NF1 (Neurofibromin 1)
    |
    TMB-H • BRAF mutation • NRAS mutation • BRAF wild-type • RAS wild-type
    |
    MSK-IMPACT
    |
    Keytruda (pembrolizumab)
    15d
    Primary large cell neuroendocrine carcinoma of pulmonary artery: a case report and literature review (PubMed, Zhonghua Jie He He Hu Xi Za Zhi)
    The patient subsequently received etoposide plus cisplatin (EP), irinotecan, and third-line combination therapy of serplulimab, anlotinib, and temozolomide. Radical surgery combined with platinum-based chemotherapy constitutes the mainstay of treatment. Molecular testing can provide a basis for personalized therapy, and multiline comprehensive treatment may offer prolonged survival benefits for patients.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation • NRAS exon 3 mutation
    |
    cisplatin • Focus V (anlotinib) • temozolomide • etoposide IV • irinotecan • Hetronifly (serplulimab)
    16d
    Correlation between Peripheral Blood Immunological Markers and Gene Mutations in Myelodysplastic Syndrome (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    Flow cytometry antibody indicators can suggest that MDS patients are prone to gene mutations related to chromatin regulation, transcriptional regulation, poor prognosis and leukemia transformation. The proportions of CD25+ T cells and lymphocytes were both closely related to the T-bet and GATA3 gene mutations.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • BCOR (BCL6 Corepressor) • IL2RA (Interleukin 2 receptor, alpha) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • SETBP1 (SET Binding Protein 1) • GATA2 (GATA Binding Protein 2) • PHF6 (PHD Finger Protein 6) • GATA3 (GATA binding protein 3)
    |
    TP53 mutation • KRAS mutation • NRAS mutation • ASXL1 mutation • EZH2 mutation
    16d
    Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors. (PubMed, Leukemia)
    Moreover, FTY720 co-treatment resensitized G12D NRAS-mutated M14(R)701 cells to gilteritinib in vivo. Co-treatment inactivated ERK, transcriptionally downregulated SPHK1, and inactivated downstream AKT, p70 S6K and BAD, with inactivation abrogated by constitutive SPHK1 expression. The clinically applicable S1PR modulators fingolimod and mocravimod resensitize NRAS-mutated FLT3-ITD AML cells to FLT3 inhibitors, supporting potential clinical efficacy.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • SPHK1 (Sphingosine Kinase 1)
    |
    NRAS mutation • FLT3-ITD mutation • FLT3 mutation • RAS mutation • NRAS Q61 • NRAS G12 • NRAS G13
    |
    Xospata (gilteritinib) • fingolimod • mocravimod (KRP-203)